Omnicell, Inc.
OMCL
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
52.2% upsideUndervalued by 52.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.01 Billion |
|---|---|
| Enterprise Value | $2.00 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.04 |
| Beta | 0.96 |
| Outstanding Shares | 45,323,000 |
Return
| Return on Equity | 1.63% |
|---|---|
| Return on Assets | 1.02% |
| Return on Invested Capital | 2.46% |
Valuation & Multiples
| P/E Ratio | 97.91 |
|---|---|
| PEG | -37.41 |
| Price to Sales | 1.55 |
| Price to Book Ratio | 1.55 |
| Enterprise Value to Revenue | 1.63 |
| Enterprise Value to EBIT | 53.46 |
| Enterprise Value to Net Income | 98 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.4411▲ 135.02% |
|---|---|
| Total Calls | 26,300▼ 82.55% |
| Total Puts | 37,900▲ 176.64% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 103.98%▲ 2.69% |
|---|---|
| Total Invested | $1.56B▼ 26.03% |
| Investors Holding | 276▲ 8.00% |
ESG Score
No data
About Omnicell, Inc.
CEO: Randall Lipps Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending like Medicare. Its decisions on tax policy directly affect Omnicell's profitability, and its influence on Medicare pricing and healthcare funding profoundly impacts Omnicell's customer base and market opportunities.
This committee directly allocates federal discretionary spending, significantly impacting funding for healthcare systems, medical research, and federal healthcare programs which are major customers or influence market demand for Omnicell's solutions.
This committee directly regulates the healthcare industry through the FDA (medical devices and software), and influences labor laws, both of which are critical to Omnicell's product development, approvals, and operational costs.
This committee's funding decisions directly impact government healthcare contractors and medical device manufacturers, including potential sales to Veterans Affairs hospitals and clinics, a key market segment for Omnicell.